PhRMA introduces an online platform connecting patients with discounted pharmaceuticals as the U.S. government pressures drug companies to reform pricing and distribution.

Explore the implications of optimizing cancer drug dosages on costs, patient care, and the pharmaceutical industry in this in-depth analysis of ongoing research and challenges.

Explore the $14.67 billion in healthcare payments in 2025, their impact on prescribing practices, and the regulatory transparency challenges faced by the industry.

Explore the regulatory challenges physicians face with pharmaceutical interactions and the implications for compliance and patient trust in the medical field.

Pharmaceutical companies agree to reduce Medicare prices for 15 prescription drugs, potentially saving billions in taxpayer and patient costs under new negotiation rules starting in 2027.

Stay informed with Pharma Pulse podcast, delivering the latest trends in pharmaceutical access, supply chain logistics, data technology, and healthcare innovation for industry professionals.

President Trump's executive order and CMS initiatives mark significant moves to reduce drug prices through broadened Medicare price negotiations including Part B drugs, impacting pharmaceutical industry dynamics and regulatory compliance.

President Trump signs an executive order setting a 30-day deadline for drugmakers to lower prescription drug prices in the U.S. or face new federal limits tied to international prices.

The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.

The Medicare for All Act aims to expand Medicare to cover all Americans comprehensively, eliminating premiums and deductibles while addressing health care affordability and systemic inefficiencies.